Daré Bioscience(DARE)

Search documents
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Newsfilter· 2024-04-23 12:00
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it will receive a pay ...
Daré Bioscience(DARE) - 2023 Q4 - Earnings Call Transcript
2024-03-29 00:47
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting Officer Conference Call Participants Douglas Tsao - H.C. Wainright Will Hidell - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company’s Fourth Quarter Financial Results and to provide a General Business Update. This call is being recorded. My name is ...
Daré Bioscience(DARE) - 2023 Q4 - Annual Report
2024-03-28 20:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 Securities registered unde ...
Daré Bioscience(DARE) - 2023 Q4 - Annual Results
2024-03-28 12:05
Financial Performance - Daré Bioscience reported total revenue of approximately $2.8 million for the year ended December 31, 2023, including a $1.0 million payment in July and a $1.8 million milestone payment in October from collaborator Organon related to XACIATO[21] - Total revenue for 2023 was $2,807,885, a decrease of 72.1% compared to $10,000,000 in 2022[38] - The company recognized a net loss of approximately $30.1 million for 2023, with general and administrative expenses of approximately $12.1 million, up about 8% compared to the prior year[21] - Net loss for 2023 was $30,161,391, compared to a net loss of $30,947,738 in 2022, representing a 2.5% improvement[38] - Comprehensive loss for 2023 was $30,170,976, compared to $31,144,076 in 2022, showing a 3.1% improvement[38] - Loss per common share for 2023 was $0.35, slightly improved from $0.37 in 2022[38] - Cash and cash equivalents decreased to $10,476,056 in 2023 from $34,669,605 in 2022, a decline of 69.7%[38] - Total assets decreased to $21,282,215 in 2023 from $43,826,383 in 2022, a reduction of 51.4%[38] - Total liabilities decreased to $26,329,855 in 2023 from $32,714,273 in 2022, a decrease of 19.5%[38] - Operating expenses for 2023 were $33,747,765, down 18.5% from $41,385,488 in 2022[38] Research and Development - Research and development expenses were approximately $21.5 million in 2023, down from approximately $30.0 million in the prior year, primarily due to costs associated with clinical studies[21] - Daré commenced the Phase 3 clinical study for its hormone-free monthly intravaginal contraceptive candidate Ovaprene in December 2023, with recruitment currently underway at 17 sites across the U.S.[10] - The FDA has cleared the investigational new drug application for DARE-VVA1, a non-hormonal treatment for sexual pain, allowing Daré to plan for a Phase 2 clinical study[18] - Positive topline results were announced for DARE-PDM1, an investigational formulation of diclofenac for treating menstrual cramping pain, following a Phase 1 study[16] - Daré anticipates providing updates on the FDA feedback and Phase 3 study design for Sildenafil Cream in 2Q-2024[14] Collaborations and Milestones - The first shipment of XACIATO™ triggered a $1.8 million milestone payment from Organon, and the product is now available nationwide by prescription[7] - Daré is eligible to receive double-digit royalties based on net sales of XACIATO and up to $180 million in potential milestone payments from Organon[8] Future Outlook - The company expects a reduction in 2024 general and administrative expenses to approximately $10.0 million, despite projected accrual-based non-cash expenses[21] - The weighted average number of common shares outstanding increased to 87,303,701 in 2023 from 84,571,805 in 2022[38] Recognition - The company has been recognized for its contributions to women's health and innovation, with leadership accolades in 2022 and 2023[33]
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Newsfilter· 2024-01-31 13:00
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sildenafil Cream) for the treatment of female sexual arousal disorder (FSAD) to a Phase ...
Daré Bioscience Announces Executive Team and Board of Directors Changes
Newsfilter· 2024-01-26 21:30
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better refl ...
Daré Bioscience(DARE) - 2023 Q3 - Earnings Call Transcript
2023-11-10 02:56
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Conference Call Participants Catherine Novack - Jones Trading Doug Tsao - H.C. Wainright Operator Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update. This call is being recorded. My name ...
Daré Bioscience(DARE) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of I ...
Daré Bioscience(DARE) - 2023 Q2 - Earnings Call Presentation
2023-08-10 23:59
DARÉ IN ITALIAN, IT MEANS "TO GIVE." IN ENGLISH, IT MEANS "TO BE BOLD." Women At Daré Bioscience, women's health is Our Sole Focus. Innovation in women's health needs to be a priority. We are working hard to identify and advance new therapies that provide additional choices and improve outcomes so that we can make a difference in the lives of women everywhere. Daré Programs Update, 08.10.2023 www.darebioscience.com 1 This presentation is for informational purposes only and is not an offer to sell or a solic ...
Daré Bioscience(DARE) - 2023 Q2 - Earnings Call Transcript
2023-08-10 23:54
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Commercial Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Catherine Novack - Jones Research Operator Welcome to the conference hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended June 30, 2023, and to provide a General Business Update. T ...